Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 110 participants.
Also called NCT04095793
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 110 participants
- Sponsor
- Theravance Biopharma
- Registry
-
NCT04095793 -
2019-002425-30
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Bulgaria, Canada, Denmark, Estonia, France, Germany, Israel, Italy, New Zealand, Poland, Portugal, Russia, Spain, Ukraine, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT04095793. Allocation not applicable; no masking; primary purpose treatment. Start 2019-09-19 (actual); primary completion 2021-11-12 (actual). Results posted on 2022-11-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
- Acronym
- OAK
- Condition
- Symptomatic Neurogenic Orthostatic Hypotension
- Intervention (Drug)
- ampreloxetine
- Lead sponsor
- Theravance Biopharma
Record details
- Record id
cardio:ct-nct04095793- Content hash
496a96defa1ee30c93d456c37322edf4470805116b9c6048bb54e2dc8dace8dd